LOADING

Type to search

Ananth Sridhar, 29

Share

It would be a bit of an understatement to say that Ananth Sridhar has always shown promise. While at Stanford University, he founded a local chapter of a student stem-cell research organization and received the Genentech Outstanding Student Award, which recognizes outstanding students in disciplines related to chemical and biological engineering. He then graduated Harvard Business School at 25 years old — four years younger than the typical graduate.

Sridhar then went on to join Regeneron Pharmaceuticals’ highly selective executive leadership development program, which seeks to develop future leaders at the company and in the industry.

In his current role, Sridhar contributes to the clinical development strategy for medicines by identifying patient populations that may benefit from them, sharing insights on market dynamics and generating innovative ways to design clinical experiments to optimize the availability of and access to those medicines. “Most of my days are spent working with research and clinical scientists to develop and commercialize novel medicines,” Sridhar says. “It’s a lot of interaction with incredibly smart and talented colleagues/friends at Regeneron.”

Furthermore, in what he cites as his career highlight thus far, Sridhar has been involved in the lengthy FDA-approval process and the commercialization of two novel antibody medicines developed at Regeneron. “Each of these experiences has been remarkably fulfilling, especially in thinking about how these molecules may change the lives of patients and their loved ones,” he says.  

Previous Article
Next Article

You Might also Like